Novo Nordisk’s Frehemgo weight-loss drug approved in Saudi Arabia, under FDA review

The Saudi green light matters less as a standalone market than as a signal of how Novo Nordisk is sequencing its global rollout while the far more consequential FDA review is still pending. The Gulf approval gives the company a regulated commercial foothold outside its core Western markets, but the real value hinges on whether U.S. and other major regulators follow. For now, the item is a reminder that approval timelines, not launch announcements, will drive the competitive picture in weight-loss drugs. Whether the FDA review advances on a comparable track is the open question.